Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitosis associated long intergenic non-coding RNA 1 (MALINC1)
- Target
- MALINC1
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
Mitosis associated long intergenic non-coding RNA 1 (MALINC1) is a cytoplasmic long non-coding RNA highly expressed in certain subtypes of breast cancer, particularly in luminal A/B tumors and ductal carcinoma in situ. MALINC1 is modulated by the estrogen–estrogen receptor axis and has been shown to be associated with oncogenic processes, including extracellular matrix remodeling, increased cell adhesion and migration, immune response modulation, and activation of the AP-1 signaling pathway. High MALINC1 expression correlates with poorer outcomes and is considered a biomarker for prognosis and for prediction of response to immunotherapy in breast cancer. It is not a conventional receptor, enzyme, or drug target but represents a regulatory RNA of emerging interest in oncology research.
- Other names
- MA-linc1Mitosis-associated long intergenic non-coding RNA 1MALINC1 (standard abbreviation)
02
Biological functions
Regulation of immune responseExtracellular matrix remodelingCell adhesionCell migrationActivation of AP-1 signaling pathwayEstrogen-estrogen receptor modulation
03
Disease associations
Cancer
04
Biomarkers
MALINC1 expression as a prognostic and predictive biomarker for breast cancer progression and potential immunotherapy response, especially in luminal and basal-like subtypes
Beyond the preview
Go deeper on Mitosis associated long intergenic non-coding RNA 1 (MALINC1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mitosis associated long intergenic non-coding RNA 1 (MALINC1).